Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is rated on a scale of 1 to 10 and is based on these factors:
1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.
MEX:ILMN vs MTD, DGX, LH: Profitability Rank Comparison
For the Diagnostics & Research subindustry, Illumina's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Illumina Profitability Rank vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Illumina's Profitability Rank falls into.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The rank is rated on a scale of 1 to 10. A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.
Illumina has the Profitability Rank of 6.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Illumina (MEX:ILMN) has a Profitability Rank of 6 as of Jun. 2026. Profitability and Growth ranks a company based on its profit margins and earnings growth. View historical data on Illumina and its competitors. This is 33% below median its historical median of 9.00. Over the past decade, Illumina's Profitability Rank has ranged from 6.00 to 10.00.
Is Illumina's Profitability Rank too high?
Illumina's current Profitability Rank of 6 is 33% below median its 10-year median of 9.00. Over the past 10 years, this metric has ranged from a low of 6.00 to a high of 10.00. Overall, Illumina has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Illumina's Profitability Rank compare to MTD and DGX?
Illumina's Profitability Rank of 6 can be compared against companies in the Medical Diagnostics & Research industry. Historically, Illumina's own Profitability Rank has ranged from 6.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Profitability Rank for a Medical Diagnostics & Research company?
A good Profitability Rank depends on the Medical Diagnostics & Research industry context. However, Profitability Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Profitability Rank mean?
A high Profitability Rank can signal that a stock is expensive relative to its fundamentals. Profitability and Growth ranks a company based on its profit margins and earnings growth. View historical data on Illumina and its competitors. Illumina's current Profitability Rank is 6, which is 33% below median its own 10-year median of 9.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Based on GuruFocus' analysis, Illumina (MEX:ILMN) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN2,165.86, compared to a current price of MXN3,375.00 — trading 55.8% above its estimated fair value. The current Profitability Rank is 6, which is 33% below median its 10-year median of 9.00. Illumina's overall GF Score™ is 57/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Profitability Rank calculated?
Profitability Rank is calculated from a company's financial statements. For Illumina (MEX:ILMN), the current Profitability Rank is 6 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Illumina (MEX:ILMN) Overvalued in 2026?
Based on GuruFocus' analysis, Illumina stock appears to be overvalued.
The current stock price of MXN3,375.00 is trading 55.8% above its estimated GF Value™ of MXN2,165.86.
GuruFocus considers Illumina to be Significantly Overvalued.
Key valuation signals for MEX:ILMN:
Profitability Rank: 6 (33% below median its 10-year median of 9.00)
GF Value™: MXN2,165.86 vs. price of MXN3,375.00 (55.8% above fair value)
No single metric tells the full story. See the MEX:ILMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
57GF Score
Get the complete analysis for MEX:ILMN
Profitability Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ILMN has been successfully added to your 
